Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Non-blinded, Two-way Crossover Study to Assess Bioequivalence Between a Rivaroxaban 10 mg Orally Disintegrating Tablet Administered With Water or Without Water and a Rivaroxaban 10 mg Film-coated Tablet in Japanese Healthy Male Adult Subjects

NCT04511611 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT04511611
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04511611 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Non-blinded, Two-way Crossover Study to Assess Bioequivalence Between a Rivaroxaban 10 mg Orally Disintegrating Tablet Administered With Water or Without Water and a Rivaroxaban 10 mg Film-coated Tablet in Japanese Healthy Male Adult Subjects
Lead sponsor
Bayer
Phase
Phase 1
Overall status
Completed
Start date
January 24, 2019
Completion date
May 13, 2019
Enrollment
80 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

clinical pharmacology